Xurodopa 110 Tablet combines Levodopa 100mg and Carbidopa 10mg, a widely prescribed therapy for Parkinson’s disease. Levodopa replenishes dopamine levels in the brain, while Carbidopa prevents its premature conversion outside the brain, enhancing efficacy and reducing side effects like nausea.
Belonging to the neurology and CNS segment, Xurodopa 110 is indicated for patients with motor symptoms including tremors, rigidity, and bradykinesia. Its combination formulation ensures improved patient adherence and symptom control.
The tablet is particularly useful in long-term Parkinson’s management, allowing dose titration based on clinical response. Hospitals, neurology clinics, and specialty pharmacies show high demand for this therapy due to its proven effectiveness.
For PCD pharma franchise partners, wholesalers, exporters, and third-party manufacturers, Xurodopa 110 Tablet offers a profitable B2B opportunity in the anti-Parkinson segment, providing stable demand and growth potential across India.
Nausea, vomiting, dizziness, headache, low blood pressure, sleep disturbances, and involuntary movements (dyskinesia). Rarely, it may cause hallucinations, severe mood changes, or heart rhythm disturbances.
Used in the treatment of Parkinson’s disease and parkinsonian symptoms. It helps manage tremors, rigidity, bradykinesia (slowness of movement), and improves overall mobility and daily functioning.
Take Xurodopa 110 Tablet exactly as prescribed, preferably at the same time each day. Do not stop abruptly, as this may worsen symptoms. Inform your doctor if you have heart disease, liver/kidney problems, or psychiatric disorders.
Store below 25°C in a cool, dry place away from sunlight and moisture. Keep out of reach of children.